Tags

Type your tag names separated by a space and hit enter

Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute purulent bacterial bronchitis.
Clin Ther. 1992 Mar-Apr; 14(2):166-77.CT

Abstract

In this single-blind study, 488 patients with acute bronchitis were randomly assigned to receive 400 mg of loracarbef twice daily or 500/125 mg of amoxicillin/clavulanate three times daily for seven days. Treatment efficacy was evaluated in 98 patients treated with loracarbef and in 99 treated with amoxicillin-clavulanate in whom pretreatment positive cultures of pathogens susceptible to both study drugs were found. Streptococcus pneumoniae, Haemophilus influenzae, Moraxella (Branhamella) catarrhalis, and Klebsiella pneumoniae were isolated in pure or mixed cultures in 64% of the evaluable patients; S pneumoniae was found in 26%. Among the evaluable patients, the rate of favorable clinical responses (cure and improvement) in the loracarbef group (96 of 98 patients; 98.0%) was similar to that in the amoxicillin/clavulanate group (96 of 99 patients; 97.0%); the favorable bacteriologic response rates were also similar (93.7% vs 92.9%, respectively). Eight patients in the loracarbef group and nine in the amoxicillin/clavulanate group discontinued treatment because of adverse events. The events were presumed to be drug related in five of the loracarbef group and in seven of the amoxicillin/clavulanate group. During therapy, diarrhea was the most frequently reported event in both groups. However, it occurred in only 8.2% of the loracarbef-treated patients compared with 22.5% of the amoxicillin/clavulanate patients (P less than 0.001). It is concluded that both loracarbef and amoxicillin/clavulanate are safe and effective in the treatment of acute purulent bacterial bronchitis.

Authors+Show Affiliations

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

1611641

Citation

Dere, W H., et al. "Loracarbef (LY163892) Versus Amoxicillin/clavulanate in the Treatment of Acute Purulent Bacterial Bronchitis." Clinical Therapeutics, vol. 14, no. 2, 1992, pp. 166-77.
Dere WH, Farlow D, Therasse DG, et al. Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute purulent bacterial bronchitis. Clin Ther. 1992;14(2):166-77.
Dere, W. H., Farlow, D., Therasse, D. G., Jacobson, K. D., & Guerra, F. J. (1992). Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute purulent bacterial bronchitis. Clinical Therapeutics, 14(2), 166-77.
Dere WH, et al. Loracarbef (LY163892) Versus Amoxicillin/clavulanate in the Treatment of Acute Purulent Bacterial Bronchitis. Clin Ther. 1992 Mar-Apr;14(2):166-77. PubMed PMID: 1611641.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute purulent bacterial bronchitis. AU - Dere,W H, AU - Farlow,D, AU - Therasse,D G, AU - Jacobson,K D, AU - Guerra,F J, PY - 1992/3/1/pubmed PY - 1992/3/1/medline PY - 1992/3/1/entrez SP - 166 EP - 77 JF - Clinical therapeutics JO - Clin Ther VL - 14 IS - 2 N2 - In this single-blind study, 488 patients with acute bronchitis were randomly assigned to receive 400 mg of loracarbef twice daily or 500/125 mg of amoxicillin/clavulanate three times daily for seven days. Treatment efficacy was evaluated in 98 patients treated with loracarbef and in 99 treated with amoxicillin-clavulanate in whom pretreatment positive cultures of pathogens susceptible to both study drugs were found. Streptococcus pneumoniae, Haemophilus influenzae, Moraxella (Branhamella) catarrhalis, and Klebsiella pneumoniae were isolated in pure or mixed cultures in 64% of the evaluable patients; S pneumoniae was found in 26%. Among the evaluable patients, the rate of favorable clinical responses (cure and improvement) in the loracarbef group (96 of 98 patients; 98.0%) was similar to that in the amoxicillin/clavulanate group (96 of 99 patients; 97.0%); the favorable bacteriologic response rates were also similar (93.7% vs 92.9%, respectively). Eight patients in the loracarbef group and nine in the amoxicillin/clavulanate group discontinued treatment because of adverse events. The events were presumed to be drug related in five of the loracarbef group and in seven of the amoxicillin/clavulanate group. During therapy, diarrhea was the most frequently reported event in both groups. However, it occurred in only 8.2% of the loracarbef-treated patients compared with 22.5% of the amoxicillin/clavulanate patients (P less than 0.001). It is concluded that both loracarbef and amoxicillin/clavulanate are safe and effective in the treatment of acute purulent bacterial bronchitis. SN - 0149-2918 UR - https://www.unboundmedicine.com/medline/citation/1611641/Loracarbef__LY163892__versus_amoxicillin/clavulanate_in_the_treatment_of_acute_purulent_bacterial_bronchitis_ DB - PRIME DP - Unbound Medicine ER -